|1.||Figueiredo-Pereira, Maria E: 7 articles (10/2012 - 06/2005)|
|2.||Thiemermann, Christoph: 4 articles (12/2004 - 07/2002)|
|3.||Ogburn, Kenyon D: 3 articles (08/2006 - 05/2006)|
|4.||Wang, Zhiyou: 3 articles (07/2006 - 06/2005)|
|5.||Collin, Marika: 3 articles (12/2004 - 08/2003)|
|6.||Uchida, Koji: 2 articles (10/2014 - 06/2005)|
|7.||Myeku, Natura: 2 articles (10/2012 - 07/2009)|
|8.||Drew, Paul D: 2 articles (04/2005 - 09/2004)|
|9.||Roman, Jesse: 2 articles (03/2004 - 02/2004)|
|10.||Shibata, Takahiro: 1 article (10/2014)|
|1.||Acute Lung Injury
01/01/2009 - "Our studies establish the first model of inflammation in which administration of an endogenous highly reactive product of inflammation, PGJ2, recapitulates key aspects of PD. "
01/01/2014 - "Erratum to "15-Deoxy-γ12,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPARγ and Reduction in NF-κB Activity"."
07/01/2009 - "Our data suggest a potential sequence of events triggered by the neurotoxic product of inflammation PGJ2 leading to tau pathology. "
04/01/2005 - "The prostaglandin J2 derivative 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a very active compound with important effects on inflammation, apoptosis, and cell growth processes. "
01/01/2004 - "As the synthesis of PGJ2 is increased at sites of inflammation, our results may suggest a possible mechanism for endothelial damage."
|4.||Melanoma (Melanoma, Malignant)
03/01/2014 - "PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2."
11/01/1984 - "PGJ2 was potent in inhibiting proliferation of cultured vascular smooth muscle cells, mouse melanoma cells and mouse fibroblasts. "
04/01/1986 - "Towards the end of our study, we obtained PGJ2 and found that it was as cytotoxic as PGD2 for L1210 cells but was more lethal for human melanoma cells. "
10/01/2003 - "Ciglitazone and PGJ2 inhibited melanoma cell proliferation in a dose-dependent manner. "
10/01/1984 - "In rabbit aortic smooth muscle cells and mouse B16BL6 melanoma cells, order of potency was: 12-HETE greater than PGJ2 greater than PGA1 greater than or equal to PGE1 greater than PGE2 greater than or equal to PGD2 greater than or equal to PGA2. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "The present study compared the anticancer effects of PGJ2 on estrogen receptor alpha (ERα)-positive (MCF-7) and ERα-negative (MDA-MB-231) human breast cancer cells. "
02/20/2003 - "Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy."
01/01/2013 - "An endogenous ligand of PPARγ, 15-deoxy-Δ12,14 prostaglandin J2 (PGJ2), is emerging as a potent anticancer agent but the exact mechanism has not been fully elucidated, especially in breast cancer. "
09/01/2001 - "We studied the effects of low-, moderate-, and high-dose treatment of the PPARgamma ligands 15-deoxy-delta1214 prostaglandin J2 (15dPGJ2) and troglitazone (TGZ) on parameters of cell growth, differentiation, and apoptosis in the epithelial breast cancer cell line MDA-MB-231. "
|3.||Estrogen Receptor alpha
|7.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)